These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 19937596

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin.
    Chen Z, Komatsu K, Prestigiacomo A, Stamey TA.
    J Urol; 1996 Oct; 156(4):1357-63. PubMed ID: 8808871
    [Abstract] [Full Text] [Related]

  • 3. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
    Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT.
    Prostate; 2001 Jun 15; 48(1):1-6. PubMed ID: 11391681
    [Abstract] [Full Text] [Related]

  • 4. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.
    Villoutreix BO, Lilja H, Pettersson K, Lövgren T, Teleman O.
    Protein Sci; 1996 May 15; 5(5):836-51. PubMed ID: 8732755
    [Abstract] [Full Text] [Related]

  • 5. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer.
    Lilja H.
    Scand J Clin Lab Invest Suppl; 1995 May 15; 220():47-56. PubMed ID: 7544478
    [Abstract] [Full Text] [Related]

  • 6. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O.
    Cancer Res; 1991 Jan 01; 51(1):222-6. PubMed ID: 1703033
    [Abstract] [Full Text] [Related]

  • 7. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM, Finne P, Leinonen J, Stenman UH.
    Scand J Clin Lab Invest Suppl; 2000 Jan 01; 233():51-8. PubMed ID: 11317942
    [Abstract] [Full Text] [Related]

  • 8. Complex formation between PSA isoenzymes and protease inhibitors.
    Leinonen J, Zhang WM, Stenman UH.
    J Urol; 1996 Mar 01; 155(3):1099-103. PubMed ID: 8583572
    [Abstract] [Full Text] [Related]

  • 9. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
    Väisänen V, Lövgren J, Hellman J, Piironen T, Lilja H, Pettersson K.
    Prostate Cancer Prostatic Dis; 1999 Mar 01; 2(2):91-97. PubMed ID: 12496845
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Physicochemical conditions affecting the formation/stability of serum complexes and the determination of prostate-specific antigen (PSA).
    Kioukia-Fougia N, Christofidis I, Strantzalis N.
    Anticancer Res; 1999 Mar 01; 19(4B):3315-20. PubMed ID: 10652627
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Concentrations of free form and complex form of prostate-specific antigen in serum of alpha 2 macroglobulin deficient patients with prostatic carcinoma].
    Kanoh Y, Jimbo S, Shibuya M, Matsuyama N, Mashiko T, Tanaka T, Egawa S, Ohtani H.
    Rinsho Byori; 1998 Sep 01; 46(9):923-9. PubMed ID: 9800478
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera.
    Heeb MJ, España F, Gittes RF, Griffin JH.
    Biochem Mol Biol Int; 1995 Nov 01; 37(5):917-23. PubMed ID: 8624498
    [Abstract] [Full Text] [Related]

  • 16. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
    Finne P, Zhang WM, Auvinen A, Leinonen J, Määttänen L, Rannikko S, Tammela TL, Stenman UH.
    J Urol; 2000 Dec 01; 164(6):1956-60. PubMed ID: 11061890
    [Abstract] [Full Text] [Related]

  • 17. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
    Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J.
    Cancer Res; 1995 Jun 01; 55(11):2455-62. PubMed ID: 7538903
    [Abstract] [Full Text] [Related]

  • 18. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice.
    Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ.
    Anticancer Res; 1999 Jun 01; 19(2A):893-902. PubMed ID: 10368631
    [Abstract] [Full Text] [Related]

  • 19. [Identification physico-chemical properties and immunochemical characteristic of prostate specific antigen and its complexes with protease inhibitors].
    Chekhonin VP, Mazo EB, Riabukhin IA, Grigor'ev ME.
    Vopr Med Khim; 1997 Jun 01; 43(3):165-71. PubMed ID: 9273780
    [Abstract] [Full Text] [Related]

  • 20. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin.
    Lilja H.
    Urol Clin North Am; 1993 Nov 01; 20(4):681-6. PubMed ID: 7505976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.